Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 14/20 | 0.56 |
| ▸ | STAT6 | P42226 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13265461 | 0.82 | SLC29A1 (0.69) | SLC29A1STAT6 | |
| SCHEMBL13239708 | 0.82 | SLC29A1 (0.66) | SLC29A1STAT6PDE4APDE4BPDE4C | |
| SCHEMBL13239703 | 0.80 | NPC1 (0.61) | SLC29A1TSHR | |
| SCHEMBL13239681 | 0.78 | HPGD (0.43) | SLC29A1 | |
| SCHEMBL15165603 | 0.78 | HPGD (0.43) | SLC29A1 | |
| SCHEMBL12378913 | 0.77 | AHCY (0.53) | SLC29A1STAT6 | |
| SCHEMBL14064196 | 0.77 | AHCY (0.53) | SLC29A1STAT6 | |
| SCHEMBL27427587 | 0.75 | SLC29A1 (0.76) | SLC29A1STAT6PDE4APDE4BPDE4C | |
| SCHEMBL15165598 | 0.75 | HIF1A (0.46) | — | |
| SCHEMBL11986896 | 0.75 | ADORA3 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501931-B2 | Convertible nucleoside derivatives | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, NUDT14 | SLC29A1 19/4885STAT6 4656/4885PDE4A 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.